- Home
- SPPP vs ACRS Comparison
SPPP vs ACRS Comparison
Compare SPPP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- ACRS
- Stock Information
- Founded
- SPPP 2011
- ACRS 2012
- Country
- SPPP Canada
- ACRS United States
- Employees
- SPPP N/A
- ACRS N/A
- Industry
- SPPP
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- ACRS Health Care
- Exchange
- SPPP NYSE
- ACRS Nasdaq
- Market Cap
- SPPP 139.1M
- ACRS 132.0M
- IPO Year
- SPPP N/A
- ACRS 2015
- Fundamental
- Price
- SPPP $9.15
- ACRS $2.93
- Analyst Decision
- SPPP
- ACRS Strong Buy
- Analyst Count
- SPPP 0
- ACRS 5
- Target Price
- SPPP N/A
- ACRS $11.00
- AVG Volume (30 Days)
- SPPP 263.6K
- ACRS 1.0M
- Earning Date
- SPPP 01-01-0001
- ACRS 11-06-2024
- Dividend Yield
- SPPP N/A
- ACRS N/A
- EPS Growth
- SPPP N/A
- ACRS N/A
- EPS
- SPPP N/A
- ACRS N/A
- Revenue
- SPPP N/A
- ACRS $27,079,000.00
- Revenue This Year
- SPPP N/A
- ACRS N/A
- Revenue Next Year
- SPPP N/A
- ACRS N/A
- P/E Ratio
- SPPP N/A
- ACRS N/A
- Revenue Growth
- SPPP N/A
- ACRS 26.35
- 52 Week Low
- SPPP $8.55
- ACRS $0.86
- 52 Week High
- SPPP $11.39
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SPPP 40.95
- ACRS 43.89
- Support Level
- SPPP $9.22
- ACRS $2.71
- Resistance Level
- SPPP $9.37
- ACRS $3.12
- Average True Range (ATR)
- SPPP 0.12
- ACRS 0.27
- MACD
- SPPP 0.02
- ACRS -0.14
- Stochastic Oscillator
- SPPP 36.92
- ACRS 9.85
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.